Pediatric Clinical Trials
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
This is a multicenter, open-label study to evaluate the safety and efficacy of treatment with brentuximab vedotin (SGN-35) in patients who have previously participated in an brentuximab vedotin study.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- drug: brentuximab vedotin
Eligibility
Inclusion Criteria:
- Participated in a previous brentuximab vedotin study.
- CD30-positive hematologic malignancy.
- At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For
retreatment, patients must have previously achieved either complete or partial
remission with brentuximab vedotin and experienced disease progression after
discontinuing the prior brentuximab vedotin study.
Exclusion Criteria:
Withdrew consent to participate in any prior brentuximab vedotin study.
Ages Eligible for Study
6 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061
Not Recruiting